Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Nafcillin
Drug ID BADD_D01515
Description A semi-synthetic antibiotic related to penicillin, Naficillin is a narrow-spectrum beta-lactam antibiotic drug. It is a beta-lactamase-resistant penicillin that is indicated for the treatment of Staphylococcal infections caused by strains that are resistant to other penicillins, except those caused by MRSA. It may be used as a first-line therapy in Methicillin-Sensitive *Staphylococcus aureus* infections [A20360].
Indications and Usage Indicated in the treatment of infections caused by penicillinase-producing staphylococci which have demonstrated susceptibility to the drug.
Marketing Status approved; investigational
ATC Code J01CF06
DrugBank ID DB00607
KEGG ID D08242
MeSH ID D009254
PubChem ID 8982
TTD Drug ID D0A0JH
NDC Product Code 44567-223; 0338-1019; 44567-221; 63323-330; 0338-1017; 44567-222
UNII 4CNZ27M7RV
Synonyms Nafcillin | Naphthamidopenicillin | Nafcil | Nafcillin Sodium | Sodium, Nafcillin | Nafcillin, Monosodium Salt, Anhydrous | Sodium Nafcillin | Nafcillin, Sodium
Chemical Information
Molecular Formula C21H22N2O5S
CAS Registry Number 147-52-4
SMILES CCOC1=C(C2=CC=CC=C2C=C1)C(=O)NC3C4N(C3=O)C(C(S4)(C)C)C(=O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Pseudomembranous colitis11.02.02.002; 07.19.01.003--Not Available
Pyrexia08.05.02.0030.000122%
Rash23.03.13.0010.000598%Not Available
Rash erythematous23.03.13.0290.000049%Not Available
Rash pruritic23.03.13.0300.000049%Not Available
Renal failure20.01.03.0050.000107%Not Available
Renal tubular disorder20.05.03.004--Not Available
Respiratory arrest22.02.01.0090.000049%Not Available
Serum sickness12.02.08.004; 10.01.03.004--
Shock24.06.02.002--Not Available
Skin exfoliation23.03.07.003--Not Available
Skin necrosis23.03.03.011--Not Available
Stomatitis07.05.06.005--
Swelling08.01.03.0150.000049%Not Available
Swollen tongue23.04.01.014; 10.01.05.015; 07.14.02.0030.000165%Not Available
Thrombophlebitis24.01.02.001--Not Available
Tongue discolouration07.14.02.006--Not Available
Urticaria10.01.06.001; 23.04.02.0010.000355%
Vomiting07.01.07.0030.000228%
Yellow skin23.03.03.042; 09.01.01.009; 08.01.03.0460.000049%Not Available
Tubulointerstitial nephritis20.05.02.0020.000374%Not Available
Peripheral swelling08.01.03.053; 02.05.04.0150.000049%Not Available
Protein urine present13.13.02.006--Not Available
Musculoskeletal discomfort15.03.04.001--Not Available
Type IV hypersensitivity reaction10.01.03.0220.000122%Not Available
Inflammation10.02.01.089; 08.01.05.007--Not Available
Ill-defined disorder08.01.03.049--Not Available
Renal impairment20.01.03.0100.000131%Not Available
Bone marrow failure01.03.03.005--
Soft tissue necrosis24.04.02.007; 15.03.02.002--
The 3th Page    First    Pre   3 4    Next   Last    Total 4 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene